EOLSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Evolus, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$7.36+0.26 (+3.66%)
Close on Oct 19, 2026
- Market cap
- $485.24M
- P/E (TTM)
- –
- Dividend yield
- –
Evolus, Inc. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product revenue, net | $83.35M | $72.75M | $89.22M | $68.97M | $68.70M | $68.07M | $78.96M | $60.16M | $66.22M | $58.96M | $60.67M | $49.32M | 99.1% | +21.3% |
| Service revenue | $734.00K | $390.00K | $1.08M | $0 | $688.00K | $448.00K | – | $921.00K | $687.00K | $369.00K | $328.00K | $696.00K | 0.9% | +6.7% |
By region
From the segment and revenue-disaggregation notes of Evolus's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.